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Abstract 
Purpose: To review the potential protective role of hydrogen against cisplatin-induced side effects 
during chemotherapy. 
Methods: We searched PubMed and SCOPUS using the following keywords and combinations in titles, 
keywords, abstracts and full texts: cisplatin; side effects; chemotherapy; tumor; toxicity; hydrogen; 
reactive oxidative species; and ischemic reperfusion.  
Results: The pathogenesis of cisplatin-induced side effects is suggested based on the increased level 
of reactive oxidative species (ROS). Cisplatin induces ROS-dependent platelet apoptosis via the 
extracellular signal-regulated kinase (ERK) signaling pathway, which might have contributed to cisplatin-
induced hematotoxicity, and in particular, thrombocytopenia. Molecular hydrogen has been shown to 
have therapeutic effects against damage to various organs (especially kidney, brain and liver) caused 
by ischemic reperfusion (IR) through selective elimination of the most cytotoxic ROS hydrogen radicals 
without affecting other types of ROS involved in signal transduction in vitro and in vivo.  
Conclusion: Hydrogen may not only alleviate hematotoxicity in patients with hemorrhagic tendencies 
during cisplatin-based chemotherapy, but also has a potential protective effect against other side effects 
induced by cisplatin.  
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Cis-diamminedichloroplatinum II (cisplatin) is one 
of the most effective platinum-based agents, and 
has broad spectrum anti-neoplastic effects on 
various tumors. Unfortunately, cisplatin-based 
chemotherapy is usually accompanied by several 
side effects, including nephrotoxicity, peripheral 
neuropathy, and hematologic toxicity [1], in which 
reactive oxidative species (ROS) play key roles 
[2].  
 
Cisplatin induces the generation of various ROS, 
including hydroxyl radicals, hydrogen peroxide, 
and superoxide anions, in cells [3,4]. Hydroxyl 
radicals are the most cytotoxic oxidants that 
indiscriminately interact with lipids, proteins, and 
nucleic acids, thus leading to lipid peroxidation, 
inactivation of proteins, and DNA fragments [3,4]. 
Cisplatin induces ROS-mediated platelet 
apoptosis via the extracellular signal-regulated 
kinase (ERK) signaling pathway, which might 
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contribute to cisplatin-induced hematotoxicity, 
and in particular, thrombocytopenia. Moreover, 
two anti-oxidants (N-acetylcysteine [NAC] and 
dithiothreitol [DTT]) effectively abolish ROS 
production, ERK activation, and platelet 
apoptosis elicited by cisplatin [2]. Although many 
anti-oxidants, such as NAC, vitamin E, vitamin C, 
allopurinol, erdosteine, edaravone, and 
melatonin, exhibit protective effects in animal 
models involving cisplatin treatment, high-dose 
anti-oxidants often cause other side effects and 
interfere with the anti-tumor effects of cisplatin in 
clinical applications [5-7]. Specifically, hydrogen 
peroxide and superoxide anion play key roles in 
cell proliferation, differentiation, and apoptosis as 
signaling molecules [3]. Therefore, more effective 
and safe agents are needed. 
 
Molecular hydrogen has been shown to have 
therapeutic effects against damage to various 
organs, especially the kidneys, brain, and liver 
induced caused by ischemic reperfusion (I/R) 
through selective elimination of the most 
cytotoxic ROS hydrogen radicals without 
affecting other types of ROS involved in signal 
transduction in vitro and in vivo [8-23]. 
Specifically, Ohsawa and colleagues 
[10,13,16,22] reported that molecular hydrogen 
selectively eliminates ROS levels, especially 
hydroxyl radicals, and exhibits protective effects 
in PC12 cultured cells, cell-free systems, and 
acute rat models of cerebral artery occlusion 
induced by focal ischemia and reperfusion. 
Furthermore, it has been reported that hydrogen 
inhibits ROS and oxidative stress-induced 
damage involving the hippocampus and learning 
tasks in chronic physically-restrained mouse 
models [16]. In addition, inhalation of hydrogen 
gas also inhibits liver injury caused by I/R 
through selectively abolishing hydrogical radicals 
in a mouse model [15]. Moreover, the protective 
effects of hydrogen-rich water against 
nephrotoxicity induced by cisplatin has been 
demonstrated in rat models based on dynamic 
contrast-enhanced CT (DCF-CT) analysis [10]. 
These data indicate that the beneficial effects of 
molecular hydrogen can be used to attenuate the 
injuries of various organs caused by elevated 
ROS and oxidative stress. 
 
This work is based on the hypothesize that 
hydrogen may not only alleviate hematotoxicity in 
patients with hemorrhagic tendencies during 
cisplatin-based chemotherapy, but also has 
potentially protective effects against other 





The online database, PubMed and SCOPUS, were 
searched using the following keywords and 
combinations in titles, keywords, abstracts and full 
texts: cisplatin; side effects; chemotherapy; tumor; 
toxicity; hydrogen; reactive oxidative species; and 
ischemic reperfusion.  
 
RESULTS AND DISCUSSION 
 
Compared with other known treatments, 
transfusion of hydrogen may have more 
advantages in preventing cisplatin-induced 
adverse side effects in patients receiving 
cisplatin-based chemotherapy. We reviewed 
related articles, and summarized three main 
pieces of evidence in support of our hypothesis. 
 
1) Hydrogen selectively eliminates the most 
cytotoxic ROS hydrogen radicals to generate 
innocuous water, but does not affect the other 
types of physiologically beneficial ROS involved 
in signal transduction and biological activities 
without compromising the anti-tumor effects of 
cisplatin [3]. Thus, hydrogen may not only 
alleviate hematotoxicity in patients with 
hemorrhagic tendencies during cisplatin-based 
chemotherapy, but also has potentially protective 





Figure 1: Hypothesis illustrating hydrogen antagonizing cisplatin-induced side effects in chemotherapy. ROS: 
reactive oxidative species; ERK: extracellular signal-regulated kinase 
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2) As a mild but effective anti-oxidant, hydrogen 
is much smaller in weight than most known anti-
oxidants, and is electronically neutral. Moreover, 
hydrogen can diffuse rapidly into tissues and 
cells, penetrate biomembranes, and diffuse into 
nuclei, the cytosol, and mitochondria, which are 
the main sources of ROS production, and 
selectively abolish hydroxyl radicals in living cells 
[8-23]. 
 
3) A hydrogen concentration of 1 or 2 % shows 
an efficient protective effect on organ injuries in 
animal models, and hydrogen does not explore 
or burn at a concentration < 4.7 %.   
 
4) Production of ROS is suggested in platelets 
during storage [24]. In fact, increasing periods 
without agitation induce platelet apoptotic 
cascades, including depolarization of MMP, 
down-regulation of Bcl-2, up-regulation of Bax 
and Bak, activation of caspases, and PS 
exposure, which are closely correlated with 
elevation of intracellular ROS levels during 
storage [25,26]. Furthermore, thrombin elicits 
platelet apoptosis through the production of ROS 
[27,28]. Hydrogen may protect platelet apoptosis 
and improve the quality of platelets in hydrogen 
during storage. Therefore, hydrogen may have 
the potential to be used as a new class of anti-




In conclusion, our review of the literature and 
existing data indicate that hydrogen not only 
inhibits cisplatin-induced hematotoxicity 
(especially bleeding), but also improves long-
lasting improvement in function of kidneys and 
other organs by attenuating oxidative stress, 
preventing platelet apoptosis, and providing 
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